Corrigendum to the Public Announcement for the attention of the Shareholders of

BAYER DIAGNOSTICS INDIA LIMITED ("Target Company")

Registered Office: 589, Sayajipura, Ajwa Road, Baroda – 390 019, Gujarat, India

In connection with the Public Announcement ("PA") issued by J.P. Morgan India Private Limited ("Manager to the Offer"), on behalf of Siemens AG on July 3, 2006, pursuant to and in compliance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto (the "Takeover Regulations"), the shareholders of Bayer Diagnostics India Limited are required to note the following:

1. Following execution of the Share Purchase Agreement ("SPA") between Siemens AG, Bayer AG and the Sellers in connection with the acquisition by Siemens AG of the Sale Shares, Siemens AG decided to hold the diagnostics business to be acquired by it from Bayer AG globally through its wholly-owned subsidiary, Siemens Diagnostics Holding II B.V. The purpose of this was to regularise Siemens AG's global diagnostics businesses under a single entity for administrative convenience. Accordingly, subsequent to the PA, the parties to the SPA agreed that the acquisition of the Sale Shares shall be carried out and completed by Siemens Diagnostics Holding II B.V. (an indirect wholly owned subsidiary of Siemens AG and hereinafter referred to as "Acquirer") in place and stead of Siemens AG. Consequently, on December 18, 2006, Bayer AG, Siemens AG, the Sellers and the Acquirer executed the SPA Amendment Agreement pursuant to which it was agreed, inter alia, that the Acquirer shall have all the rights and obligations of Siemens AG under the SPA and shall purchase the Sale Shares from the Sellers on the terms and conditions of the SPA in place and stead of Siemens AG.

   Pursuant to the amendment to the SPA, for the purposes of this Offer, Siemens Diagnostics Holding II B.V. ("Acquirer") will acquire the Offer Shares. Siemens AG is participating in this Offer as a "person acting in concert" with the Acquirer and will not acquire any of the Offer Shares. However, as the ultimate holding company of the Acquirer, Siemens AG guarantees the due and proper performance by the Acquirer of all its obligations under the Letter of Offer and the Takeover Regulations including but not limited to payment of the full consideration in respect of the Offer Shares purchased by the Acquirer.

   The salient features of the SPA Amendment Agreement are as follows:

   i. The Acquirer shall have all the rights and obligations of Siemens AG under the SPA and shall purchase the Sale Shares from the Sellers on the terms and conditions of the SPA in place and stead of Siemens AG;

   ii. Siemens AG shall be relieved from its rights and obligations under the SPA in full. However, Siemens AG guarantees the proper fulfillment of all of the obligations of the Acquirer pursuant to the SPA and the SPA Amendment Agreement;

   iii. The Sellers have provided capped indemnities to the Acquirer against 51% of the liabilities asserted against, incurred or suffered by the Target Company as a result of tax risks relating to periods prior to the completion of the sale and purchase of the Sale Shares by the Acquirer under the SPA;

   iv. Subject to certain specific exceptions (relating to the acquisition of other businesses which have sales competing with the business of the Target Company of less than Euro 25 million or businesses where less than 30% of the turnover competes with the Target Company), the Sellers have agreed not to compete with the diagnostics business of the Target Company for a period of 3 years from the date of completion of the sale and purchase of the Sale Shares; and

   v. The Sellers have agreed not to actively directly or indirectly solicit for employment any key employee of the diagnostics business of the Target Company, and the Acquirer has agreed not to actively solicit for employment any key employee of any of the Sellers.

2. As mentioned in the PA, the Offer is subject to the approval of the Foreign Investment Promotion Board ("FIPB") and the Reserve Bank of India ("RBI") under the Foreign Exchange Management Act, 1999 and the regulations thereunder. The FIPB has vide its letter dated September 12, 2006 granted its no-objection to Siemens AG to acquire the Offer Shares under this Offer. Further, the RBI has, vide its letter dated September 1, 2006, permitted Siemens AG to set up the required escrow and other bank accounts for the purposes of this Offer. However, in light of a change in the acquiring entity, the Acquirer applied for, and on January 22, 2007, received, FIPB approval permitting the Acquirer (instead of Siemens AG) to acquire the Offer Shares. The Acquirer will similarly approach the RBI for the required amendments to its approval dated September 1, 2006. The Acquirer and PAC will make applications to RBI and any other authority for their approval (if required) for transfer of equity shares from the eligible shareholders upon closure of the Offer once the basis of acceptance is determined.

3. The Target Company has procured the transfer of the Non-Diagnostics Business and the employees working for the Non-Diagnostics Business to Bayer MaterialScience Private Limited w.e.f. December 1, 2006. The Target Company had sent a notice of Postal Ballot dated July 25, 2006 to the members for consideration and approval of the sale of the Non-Diagnostics Business to Bayer MaterialScience Private Limited, a Bayer Group Company, on an arms length basis for a consideration of Rs. 25.74 Crores (Rupees Twenty Five Crores Seventy Four Lacs Only). The same was adopted by the members as an Ordinary Resolution on August 31, 2006. The Board of Directors of the Company, at its meeting held on December 6, 2006, approved the transfer of the Non-Diagnostics Business on and with effect from December 1, 2006. However, the consideration for the sale of the Non-Diagnostics business was revised to reflect the change in the value of the inventory and receivables together with current liabilities and provisions for the Non-Diagnostics Business and the revised figure was brought to the notice of the members of the Target Company through an advertisement dated December 6, 2006. The net increase in the value of inventories, receivables together with current liabilities and provisions of the Non-Diagnostics Business as at November 30, 2006 is Rs. 0.48 Crores (Rupees Forty Eight Lacs Only), resulting in a change in the final consideration amount for sale of the Non-Diagnostics Business from 25.74 Crores to Rs. 26.22 Crores.

   From the aforesaid consideration of Rs. 26.22 Crores, the amount available for distribution by way of interim dividend, after statutory deduction of costs, applicable taxes and transfers as required under law, was Rs. 15.13 Crores. Pursuant to the sale of the Non-Diagnostics Business, the Board of Directors of the Target Company, on December 6, 2006, declared an interim dividend of Rs. 97.00 per equity share of Rs.10 each ("Interim Dividend"). The Target Company set December 22, 2006 as the Record Date for the purpose of payment of the Interim Dividend.

4. The schedule of activities set forth in the Public Announcement dated July 3, 2006 is delayed. The original announced schedule of activities and the revised schedule of activities are as under:

	Original Time Schedule		Revised Time Schedule	
Activity	**Date**	**Day**	**Date**	**Day**
Public Announcement Date	July 3, 2006	Monday	July 3, 2006	Monday
Specified Date (for the purpose of determining the names of shareholders to whom the Letter of Offer would be sent)	July 7, 2006	Friday	July 7, 2006	Friday
Last date for a competitive bid	July 24, 2006	Monday	July 24, 2006	Monday
Date by which individual Letters of Offer will be dispatched to the shareholders	August 11, 2006	Friday	March 30, 2007	Friday
Offer Opening Date	August 25, 2006	Friday	April 6, 2007	Friday
Last date for revising the Offer Price/number of equity shares	September 4, 2006	Monday	April 16, 2007	Monday
Last Date for withdrawal by shareholders	September 8, 2006	Friday	April 20, 2007	Friday
Offer Closing Date	September 14, 2006	Thursday	April 25, 2007	Wednesday
Date by which approval/rejection would be intimated and the corresponding payment for the acquired equity shares and/or the share certificates for the rejected/withdrawn equity shares will be dispatched and/or credited to the beneficiary account in case of dematerialised equity shares	September 29, 2006	Friday	May 10, 2007	Thursday

5. Due to the delay in implementation of the Offer, the Acquirer and the PAC will pay interest of Rs. 38.63 (Rupees Thirty eight and Paise sixty three only) per fully paid share of the Target Company validly tendered and accepted under the Offer, computed at the rate of 10% per annum for the period from September 29, 2006, the original scheduled date of payment of consideration to May 10, 2007, the revised scheduled date of payment of consideration (both days inclusive).

6. A total payment of Rs. 668.08 (Rupees Six hundred sixty eight and Paise eight only), comprising of Rs. 629.45 as the Offer Price and Rs. 38.63 as interest due to delay, will be thus made for each fully paid up equity share of the Target Company validly tendered and accepted under the Offer.

7. The other terms and conditions of the Offer remain unchanged.

This Corrigendum to the Public Announcement (this "Announcement") is in continuation to the PA dated July 3, 2006 and the Corrigendum to the PA dated August 12, 2006 and published in the Financial Express, Jansatta and Sandesh. This Announcement should be read in conjunction with the PA. Terms used but not defined in this Announcement shall have the same meaning as assigned in the PA.

This Announcement is issued by the Manager to the Offer on behalf of the Acquirer. Siemens Diagnostics Holding II B.V. and Siemens AG accept full responsibility for the information contained in this Announcement. This Announcement shall also be available on SEBI's website at www.sebi.gov.in

Issued by: **MANAGER TO THE OFFER**

JPMorgan

J. P. Morgan India Private Limited
Mafatlal Centre, 9th Floor, Nariman Point, Mumbai
Phone: 91 22 22855666; Fax 91 22 6639 3091
Email: Bayerdiagnostics_Openoffer@jpmorgan.com;
Contact Person: Nitin Maheshwari

Place: Mumbai

Date: March 24, 2007

35x16 cms